PHEOCHROMOCYTOMA

This study tests a new drug that delivers radiation directly to cancer cells in people with advanced gastrointestinal neuroendocrine tumors or pheochromocytoma/paraganglioma that have already been treated with radiation therapy. The drug works by attaching to a protein found on t…

This study tests a radioactive drug called I-MIBG in people with neuroblastoma or related tumors that have not responded to standard treatments. The drug targets cancer cells directly to deliver radiation. Researchers want to see if it can shrink tumors and how safe it is. About …

This study tests a new treatment called [212Pb]VMT-α-NET for people with advanced tumors that have a specific marker (SSTR2). The treatment delivers targeted radiation to kill cancer cells while sparing healthy tissue. About 300 adults with neuroendocrine tumors or meningioma tha…

This study tests a radioactive drug called Lu-177-DOTATATE in people with rare tumors (pheochromocytoma or paraganglioma) that cannot be removed by surgery. The goal is to see if the drug can slow or stop tumor growth and to check its safety. About 130 adults will receive four do…

This early-phase trial tests a new treatment for people with advanced melanoma or other solid tumors that have spread. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack cancer cells. The goal is to find a safe dose and see if t…

This study tests a combination of two drugs—Lutathera (a targeted radiation therapy) and olaparib (a PARP inhibitor)—in children and teens aged 3 to 18 with solid tumors that have come back or not responded to standard treatment. The goal is to find the safest dose and see if the…

This study tests whether special PET scans using targeted tracers can more accurately find and stage neuroblastoma and pheochromocytoma/paraganglioma tumors than current methods. About 30 people aged 1 to 70 will receive an injection of a radioactive tracer and then have a PET sc…

This study aims to develop better methods for diagnosing and locating pheochromocytoma and paraganglioma tumors, which can cause severe high blood pressure and life-threatening complications. Researchers will use advanced blood tests, genetic testing, and imaging scans in up to 3…

This study is creating a large database to collect information about people with rare diseases like amyloidosis, sarcoidosis, and many others. Researchers will track patients' health, treatments, and outcomes over time. The goal is to better understand these conditions and improv…

This study tests a new PET scan tracer (18F-FluorThanatrace) to measure PARP-1 protein levels in people with rare adrenal tumors called pheochromocytoma or paraganglioma. About 30 adults will get one scan before their planned surgery or treatment. The results are only for researc…

This study aims to find the genes that cause pheochromocytoma and paraganglioma, rare tumors of the nervous system. Researchers will analyze DNA from up to 2,000 patients and their family members to link specific genetic changes to tumor development. The goal is to improve geneti…

This study aims to better understand how adrenal tumors develop and to evaluate new treatment options for adrenal cancer. Researchers will enroll 500 people who have an adrenal tumor seen on imaging. The goal is to improve care for patients with these rare tumors.